GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Cash Flow from Others

ACUT (Accustem Sciences) Cash Flow from Others : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Cash Flow from Others?

Accustem Sciences's cash flow from others for the three months ended in Dec. 2024 was $0.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.


Accustem Sciences Cash Flow from Others Historical Data

The historical data trend for Accustem Sciences's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Cash Flow from Others Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23 Dec24
Cash Flow from Others
-0.07 - -

Accustem Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Accustem Sciences Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Accustem Sciences Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Accustem Sciences Business Description

Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.